Progression-free survival and overall survival of anti-EGFR treated patients according to EGFR gene copy number.

<p>The hazard ratios and confidence intervals of the original discovery, validation, and combined chemorefractory patient cohorts are shown. A high <i>EGFR</i> GCN (IHC guided SISH) is associated with an improved disease outcome in all three <i>KRAS</i> wild type metastatic colorectal cancer patient cohorts treated with anti-EGFR therapy (two independent cohorts and one combined cohort of chemorefractory patients).